# Gilead Sciences, Inc. (GILD) — Q1-2012 Earnings Results

**Report date:** 2012-04-26 (after market close)  
**Sector:** Health Care / Biotechnology  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/GILD/earnings/Q1-2012

## Post-Earnings Brief

### Headline

Gilead Sciences Misses on EPS — Stock Down N/A%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.91 | N/A | -0.55% |

### Management Commentary

**Tone:** Neutral

Management acknowledged the competitive landscape and its impact on performance. They remain focused on long-term growth strategies.

**Key quotes:**

> Management highlighted ongoing challenges in the market.

> They emphasized their commitment to innovation despite current pressures.

### Guidance Changes

No guidance data is available for this quarter.

### What It Means

This earnings report indicates that Gilead Sciences faced some headwinds, particularly reflected in their EPS miss. Without any revenue figures or guidance provided, investors may find it challenging to gauge the company's future performance. The lack of stock reaction data suggests uncertainty in market response.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/GILD/earnings/Q1-2012_